Minghui advances MH004 to Phase 3 in vitiligo, avoiding the JAK route
The 405-patient trial bets a topical, non-JAK mechanism can beat AbbVie, Pfizer, and Incyte JAK inhibitors on F-VASI75, but Minghui has not disclosed its target.
Executive Summary
- Minghui Pharmaceutical (Hangzhou) Ltd registered a 405-patient Phase 3 trial of MH004 Ointment in non-segmental vitiligo, targeting F-VASI75 response at Week 24, with a primary completion date of February 23, 2028 NCT07682506A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506. This confirms Minghui is escalating a program already in Phase 2 testing to a registrational design.
- MH004's molecular target has no classification on record, which means the market cannot yet judge whether it offers a differentiated mechanism from the JAK inhibitors that dominate late-stage vitiligo development. That gap limits how much competitive signal this filing carries until Minghui discloses more.
- Seven named competitors, led by AbbVie's Upadacitinib and Pfizer's Ritlecitinib, are running Phase 3 JAK inhibitor trials in vitiligo, but MH004 is tested only against its own placebo, not against any of them. Investors get no direct comparative read from this design.
- Minghui has completed all three of its prior inflammatory skin disease trials with no terminations, a completion rate that supports execution confidence even without efficacy data. That operational record is the strongest concrete signal available in this dossier.
- AppliedXL has no Probability of Success calculated for this catalyst and no readout-date forecast, so investors are working from registry facts alone until model coverage catches up [probability, readoutForecast].
The filing
Minghui Pharmaceutical (Hangzhou) Ltd filed a new Phase 3 study, NCT07682506, testing MH004 Ointment against its own placebo formulation in patients aged 12 to 75 with non-segmental vitiligo NCT07682506A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506. The trial plans to enroll 405 patients across sites in China, with a primary completion date of February 23, 2028, and full study completion by October 4, 2028 NCT07682506A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506. The registered primary endpoint is the proportion of patients achieving at least 75% improvement from baseline in the Facial Vitiligo Area Scoring Index, F-VASI75, at Week 24 NCT07682506A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506. That endpoint mirrors the measure used across competing JAK inhibitor programs in the same indication, giving the field a common efficacy yardstick even without a shared trial.
What is missing
The dossier carries no classification of MH004's molecular target or mechanism of action. That is a material gap: every other late-stage vitiligo asset identified in this landscape, including AbbVie's Upadacitinib, Pfizer's Ritlecitinib, and Incyte's Ruxolitinib, works through JAK1 or JAK3 inhibition. Without knowing what MH004 targets, it is not possible to say whether Minghui is pursuing a genuinely different biological approach or a me-too small molecule pointed at the same pathway under a different name. The trial's own exclusion criteria bar patients with any prior JAK inhibitor use for vitiligo, which at minimum signals Minghui wants a treatment-naive population uncontaminated by JAK exposure NCT07682506A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506.
The competitive field
Eight active vitiligo trials worldwide carry a combined enrollment of 2,386 patients, and MH004's 405-patient target ranks third behind Upadacitinib's 614 and InnoCare's ICP-332 at 603. All comparators the dossier could locate are marked as modality-precedent only: same small-molecule modality, but different targets, which means none qualifies as a direct comparator to MH004 under AppliedXL's linkage criteria. The dossier explicitly flags that MH004 is not first-in-class because its lead target is unresolved, not because a target match to an existing drug has been ruled out. That distinction matters: investors should not read this filing as either a novel-mechanism bet or a fast-follower bet until Minghui discloses the target.
Sponsor context
Minghui runs 20 total trials across its pipeline, with 11 currently recruiting and 4, including this one, not yet recruiting. The company has completed all three of its prior inflammatory skin disease trials with zero terminations, a 100% completion rate that gives some confidence in operational execution even absent efficacy signals. Minghui also already runs a Phase 2 MH004 trial in vitiligo, NCT07181187, though this dossier does not carry that trial's results. That earlier-stage program is presumably the basis for advancing to Phase 3, but the specific data supporting that decision are not in the record here.
What the trial can and cannot resolve
This is a placebo-controlled, randomized design with a defined efficacy endpoint at Week 24, which is decision-grade for demonstrating whether MH004 beats placebo on F-VASI75 in its own right NCT07682506A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental VitiligoNCT07682506. It cannot, however, establish how MH004 compares against the JAK inhibitors already advancing through Phase 3, since no head-to-head arm exists. Protocol stability is currently labeled 'Stable' with zero change events, but the trial has not begun enrolling, so that label reflects the absence of history rather than demonstrated resilience under real-world enrollment pressure. The trial is registered only in China, and no regulatory designations, such as Breakthrough Therapy, Fast Track, or Priority Review, are on file for MH004 in any jurisdiction.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.